Reviva Pharmaceuticals (NASDAQ:RVPH) Raised to Strong-Buy at EF Hutton Acquisition Co. I

EF Hutton Acquisition Co. I upgraded shares of Reviva Pharmaceuticals (NASDAQ:RVPH) to a strong-buy rating in a research note published on Monday, Zacks.com reports.

Several other analysts have also recently weighed in on the company. Maxim Group reissued a hold rating on shares of Reviva Pharmaceuticals in a report on Friday, August 16th. Benchmark reissued a speculative buy rating and set a $17.00 target price on shares of Reviva Pharmaceuticals in a report on Monday, August 26th. Finally, HC Wainwright reissued a buy rating and issued a $14.00 target price on shares of Reviva Pharmaceuticals in a research report on Thursday, July 11th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of Buy and an average target price of $14.33.

Reviva Pharmaceuticals Stock Up 0.8 %

RVPH opened at $1.29 on Monday. Reviva Pharmaceuticals has a 12-month low of $0.60 and a 12-month high of $6.80. The business has a 50 day moving average of $1.08 and a 200-day moving average of $1.84. The stock has a market cap of $38.47 million, a price-to-earnings ratio of -0.81 and a beta of -0.10.

Reviva Pharmaceuticals (NASDAQ:RVPH) last announced its earnings results on Wednesday, August 14th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.02. As a group, analysts expect that Reviva Pharmaceuticals will post -0.98 earnings per share for the current year.

Institutional Investors Weigh In On Reviva Pharmaceuticals

A hedge fund recently raised its stake in Reviva Pharmaceuticals stock. Vanguard Group Inc. lifted its holdings in shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 2.8% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,001,836 shares of the company’s stock after buying an additional 26,854 shares during the period. Vanguard Group Inc. owned about 3.59% of Reviva Pharmaceuticals worth $3,787,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.